Jonel Trebicka

Medicine & Life Sciences

1. Fibrosis 100%
2. Acute-On-Chronic Liver Failure 77%
3. Liver Cirrhosis 73%
4. Liver 52%
5. Portal Hypertension 51%
6. Transjugular Intrahepatic Portasystemic Shunt 51%
7. Liver Diseases 36%
8. Elasticity Imaging Techniques 27%
9. Mortality 19%
10. Portal Pressure 19%
11. Ascites 18%
12. End Stage Liver Disease 17%
13. Survival 16%
14. Inflammation 15%
15. Surgical Portasystemic Shunt 15%
16. Portal Vein 15%
17. HIV 14%
18. Alcohols 14%
19. Hemorrhage 14%
20. Hepatic Encephalopathy 13%
21. Rifaximin 12%
22. Liver Transplantation 11%
23. Non-alcoholic Fatty Liver Disease 11%
24. Collagen Type III 11%
25. Alcoholic Liver Cirrhosis 9%
26. Extracellular Matrix 9%
27. Venous Pressure 9%
28. Therapeutics 9%
29. Chronic Disease 9%
30. Hydroxymethylglutaryl-CoA Reductase Inhibitors 9%
31. Hepatic Veins 9%
32. Albumins 8%
33. Bile Ducts 8%
34. Hemodynamics 8%
35. Biomarkers 7%
36. Sarcopenia 7%
37. Alcoholic Liver Diseases 7%
38. Hepatic Stellate Cells 7%
39. fibroblast growth factor 21 6%
40. Relaxin 6%
41. Peritonitis 6%
42. MicroRNAs 6%
43. microfibrillar protein 6%
44. Biopsy 6%
45. human MFAP4 protein 5%
46. Meta-Analysis 5%
47. Tumor Necrosis Factor Receptors 5%
48. Hepatorenal Syndrome 5%
49. Ligation 5%
50. Wounds and Injuries 5%